Gasherbrum Bio, Inc. clinical trials
A subsidiary of Structure Therapeutics
The registry lists 11 studies whose lead sponsor is Gasherbrum Bio, Inc. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 18, 2026.
- 11studies on the registry
- 4open to participants now
- 2phase 3 studies under way
- 2reach primary completion within a year
What it is testing
The drugs Gasherbrum Bio, Inc.’s studies test, most open studies first — 1 drug with a page of their own. Each count opens the studies in search.
Open now Not open: under way, finished or stopped
- aleniglipron2 in phase 34 open · 8
Coming up
2 of Gasherbrum Bio, Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- 1MMar
- AApr
- MMay
- JJun
- JJul
- 1AAug
- SSep
- OOct
- NNov
All 2
- Mar 2027Aleniglipron Renal Impairment Studyaleniglipron · NCT07946068
- Aug 2027Aleniglipron Hepatic Impairment Studyaleniglipron · NCT07872033
Add all 2 to your calendar (.ics) → With an account.
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
- Aleniglipron Hepatic Impairment StudyNov 17, 2026NCT07872033
Newly registered1
- Aleniglipron Renal Impairment StudyNov 18, 2026NCT07946068
All 11 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 23
- 24
- 25
- 426
By the year each study started. 2026 so far in the lighter column.
Registry sponsor names on this page
- Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics11 studies
Something wrong with this grouping? Tell us on the Structure Therapeutics page.
Studies
Recruiting first, then most recently updated. Showing 11 of 11. All Structure Therapeutics studies →
- Aleniglipron Renal Impairment StudyNot yet recruitingNCT07946068Phase 1
Sponsor listed in the registry: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Aleniglipron Hepatic Impairment StudyRecruitingNCT07872033Phase 1
Sponsor listed in the registry: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)RecruitingNCT07654374Phase 3
Sponsor listed in the registry: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)RecruitingNCT07654361Phase 3
Sponsor listed in the registry: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Aleniglipron Phase 2 in Type 2 Diabetes MellitusCompletedNCT07400588Phase 2
Sponsor listed in the registry: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Aleniglipron Phase 2 Body Composition StudyCompletedNCT07169942Phase 2
Sponsor listed in the registry: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- A Phase 2b, Dose-range Finding Study of the Efficacy and Safety of Multiple Doses of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityCompletedNCT06693843Phase 2
Sponsor listed in the registry: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- A Dose-Range Study of Aleniglipron (GSBR-1290) in Participants Living With Obesity or Overweight With at Least One Weight-related ComorbidityCompletedNCT06703021Phase 2
Sponsor listed in the registry: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- Phase 1b/2a Study of GSBR-1290 in Adult Overweight or Obese Healthy Subjects and Subjects With Type 2 Diabetes MellitusCompletedNCT05762471Phase 1/2
Sponsor listed in the registry: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- A Study of Multiple-ascending Doses of GSBR-1290 in Healthy Overweight/Obese ParticipantsActive, not recruitingNCT06139055Phase 1
Sponsor listed in the registry: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
- A Study of Multiple Ascending Doses of GSBR-1290 in Japanese and Non-Japanese Healthy ParticipantsCompletedNCT05893043Phase 1
Sponsor listed in the registry: Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics